Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Single-Arm Study Evaluating Toxicity, Outcomes, and Dosimetry Using an MR-guided Linear Accelerator for the Treatment of Early Stage Kidney Cancer

NCT07767500 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT07767500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07767500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Single-Arm Study Evaluating Toxicity, Outcomes, and Dosimetry Using an MR-guided Linear Accelerator for the Treatment of Early Stage Kidney Cancer
Lead sponsor
NYU Langone Health
Phase
Not applicable
Overall status
Recruiting
Start date
August 19, 2026
Completion date
October 31, 2030
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

primary renal cancer